Analytical methods knowledge base
Lot-Specific Peptide Documentation
Which records should follow the exact supplied lot, which materials may remain project-level, and how to keep representative documents from being mistaken for release evidence.
Method-aware interpretation
Read the result as a chain of evidence.
Each section connects the analytical question, reporting basis and conclusion boundary.
Separate the document layers
A specification defines intended tests and acceptance criteria. A method describes how a test is performed. A validation or qualification record supports method suitability. A COA records lot results. Stability, shipping and change-control records answer other questions. Combining these layers into one generic download can obscure which evidence actually applies.
- Map each requested claim to the record capable of supporting it.
- Identify whether a document is lot-, product-, method- or quality-system-specific.
- Do not promise a document until its scope and availability have been confirmed.
Build a traceable request
A document request should include the product, catalog identifier, lot if assigned, material form, quantity, destination and intended research or manufacturing context. This prevents a representative test result from being sent when a current lot record is required.
- Use document titles and versions rather than “all certificates.”
- State whether raw data, summary reports or signed release records are required.
- Record any redactions and explain why they do not change the interpretation.
Keep commercial availability separate from scientific validity
A document can be unavailable for confidentiality or timing reasons without proving a lot fails; conversely, a readily available certificate does not prove the method or specification is suitable. Procurement review should assess availability, authenticity, applicability and scientific adequacy as separate dimensions.
- Confirm the issuing entity and approval role.
- Check whether dates and versions match the supplied material.
- Escalate unexplained inconsistencies before relying on the record.
Decision table
What the field means—and what it does not prove
Use this table to prevent a valid analytical result from being expanded beyond its intended purpose.
↔ Swipe horizontally to read every column
| Record or question | What it can support | What it does not prove |
|---|---|---|
| Product specification | Planned attributes and acceptance criteria | Actual lot results |
| Lot COA | Released results for the identified lot | Full raw data or every quality-system control |
| Method/validation package | Procedure and evidence of fitness for purpose | That a particular lot passed |
Interpretation limits
Stop where the method stops.
- Confidential documents may require an eligibility or account review.
- Destination eligibility and material quality are different review questions.
- Document retention and authenticity should follow the applicable quality agreement.
Primary and technical sources
Records used for this guide
Sources are linked directly so the wording, date and scope can be checked independently.
- 01Source record
ICH Q6A: Specifications—Test Procedures and Acceptance Criteria
International Council for Harmonisation. Step 4 guideline, October 1999.
- 02Source record
Analytical Procedures and Methods Validation for Drugs and Biologics
U.S. Food and Drug Administration. Guidance for Industry, July 2015.
- 03Source record
ICH Q2(R2): Validation of Analytical Procedures
International Council for Harmonisation. Step 4, adopted November 2023; error-corrected 2025.
Knowledge center